360Dx

Qiagen, HTG Molecular End First Project Under CDx Development Agreement

May 22, 2018

NEW YORK (GenomeWeb) – Qiagen has terminated a project with HTG Molecular Diagnostics that is part of a multi-project assay development agreement between the companies, HTG said today in a filing with the US Securities and Exchange Commission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Qiagen, HTG Molecular End First Project Under CDx Development Agreement

To read the full story....

Breaking News

Hologic Fiscal Q1 Revenues Rise 89 Percent as Dx Testing Demand Surges

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Featured White Papers

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

What's Popular?

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

Molzym, Fraunhofer Developing Rapid Direct-From-Sample Sepsis Diagnostic Platform and Test

Sponsorships